Pluri Inc. reported a significant increase in revenue for the fiscal year ending June 30, 2025, generating $1.336 million compared to $326,000 in the previous year. This growth is attributed primarily to enhanced services provided to Contract Development and Manufacturing Organization (CDMO) clients and additional revenues from collaborations in the AgTech sector. However, the company continues to face substantial financial challenges, with a net loss of $23.25 million for the year, up from $21.34 million in the prior year. The increase in losses is largely due to foreign exchange rate fluctuations and increased operational costs.
The company has made notable strategic developments, including the acquisition of approximately 79% of Kokomodo, an innovative startup focused on sustainable cacao production, for $4.5 million in common shares. This acquisition is expected to enhance Pluri's capabilities in the AgTech sector. Additionally, Pluri launched a new business division, PluriCDMO™, in January 2024, which is already generating revenue from cell therapy manufacturing services. The company also expanded its product offerings with the introduction of a novel immunotherapy platform utilizing Mucosal Associated Invariant T (MAIT) cells aimed at treating solid tumors.
Operationally, Pluri's workforce has grown to 127 full-time employees and 15 part-time employees as of June 30, 2025. The company is actively pursuing collaborations and partnerships to expand its market presence, particularly in the fields of regenerative medicine, food technology, and agriculture technology. Despite these efforts, Pluri's accumulated deficit has reached $443.06 million, raising concerns about its ability to sustain operations without additional capital. The company is currently in discussions with the European Investment Bank regarding the restructuring of a €20 million loan due in June 2026.
Looking ahead, Pluri's management has expressed uncertainty about its ability to meet operating obligations over the next twelve months without securing additional funding. The company is exploring various avenues for capital, including potential licensing agreements and grants, to support its ongoing research and development activities. The outlook remains cautious, as the company anticipates continued losses and is focused on reducing its burn rate while striving to achieve commercial viability for its product candidates.
About Pluri Inc.
Pluri Inc. is a biotechnology company specializing in proprietary 3D cell expansion technology for scalable solutions across healthcare, food, and agriculture. Its core activities include developing cell therapies, regenerative medicine, cultivated food products, and contract manufacturing services. The company leverages its innovative platform for cell-based therapeutics, food tech, and AgTech, serving global markets with a focus on sustainability, cost-efficiency, and advanced bioprocessing.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.